Cargando…
Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls
INTRODUCTION: Gabapentin regulates pain processing by direct action on primary afferent nociceptors and dorsal horn nociresponsive neurons. Through an action at supraspinal levels, gabapentin also engages descending noradrenergic inhibitory controls that indirectly regulate spinal cord pain processi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085145/ https://www.ncbi.nlm.nih.gov/pubmed/30123855 http://dx.doi.org/10.1097/PR9.0000000000000659 |
_version_ | 1783346280096858112 |
---|---|
author | Juarez-Salinas, Dina L. Braz, Joao M. Hamel, Katherine A. Basbaum, Allan I. |
author_facet | Juarez-Salinas, Dina L. Braz, Joao M. Hamel, Katherine A. Basbaum, Allan I. |
author_sort | Juarez-Salinas, Dina L. |
collection | PubMed |
description | INTRODUCTION: Gabapentin regulates pain processing by direct action on primary afferent nociceptors and dorsal horn nociresponsive neurons. Through an action at supraspinal levels, gabapentin also engages descending noradrenergic inhibitory controls that indirectly regulate spinal cord pain processing. Although direct injection of gabapentin into the anterior cingulate cortex provides pain relief independent of descending inhibitory controls, it remains unclear whether that effect is representative of what occurs when gabapentin interacts at multiple brain loci, eg, after intracerebroventricular (i.c.v.) injection. METHODS: We administered gabapentin i.c.v. in a mouse model of chemotherapy (paclitaxel)-induced neuropathic pain. To distinguish spinal from supraspinally processed features of the pain experience, we examined mechanical hypersensitivity and assessed relief of pain aversiveness using an analgesia-induced conditioned place preference paradigm. RESULTS: Paclitaxel-treated mice showed a preference for a 100-μg i.c.v. gabapentin-paired chamber that was accompanied by reduced mechanical allodynia, indicative of concurrent engagement of descending controls. As expected, the same dose in uninjured mice did not induce place preference, demonstrating that gabapentin, unlike morphine, is not inherently rewarding. Furthermore, a lower dose of supraspinal gabapentin (30 μg), which did not reverse mechanical allodynia, did not induce conditioned place preference. Finally, concurrent injections of i.c.v. gabapentin (100 μg) and intrathecal yohimbine, an α2-receptor antagonist, blocked preference for the gabapentin-paired chamber. CONCLUSION: We conclude that pain relief, namely a reduction of pain aversiveness, induced by supraspinal gabapentin administered by an i.c.v. route is secondary to its activation of descending noradrenergic inhibitory controls that block transmission of the “pain” message from the spinal cord to the brain. |
format | Online Article Text |
id | pubmed-6085145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-60851452018-08-17 Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls Juarez-Salinas, Dina L. Braz, Joao M. Hamel, Katherine A. Basbaum, Allan I. Pain Rep Basic Science INTRODUCTION: Gabapentin regulates pain processing by direct action on primary afferent nociceptors and dorsal horn nociresponsive neurons. Through an action at supraspinal levels, gabapentin also engages descending noradrenergic inhibitory controls that indirectly regulate spinal cord pain processing. Although direct injection of gabapentin into the anterior cingulate cortex provides pain relief independent of descending inhibitory controls, it remains unclear whether that effect is representative of what occurs when gabapentin interacts at multiple brain loci, eg, after intracerebroventricular (i.c.v.) injection. METHODS: We administered gabapentin i.c.v. in a mouse model of chemotherapy (paclitaxel)-induced neuropathic pain. To distinguish spinal from supraspinally processed features of the pain experience, we examined mechanical hypersensitivity and assessed relief of pain aversiveness using an analgesia-induced conditioned place preference paradigm. RESULTS: Paclitaxel-treated mice showed a preference for a 100-μg i.c.v. gabapentin-paired chamber that was accompanied by reduced mechanical allodynia, indicative of concurrent engagement of descending controls. As expected, the same dose in uninjured mice did not induce place preference, demonstrating that gabapentin, unlike morphine, is not inherently rewarding. Furthermore, a lower dose of supraspinal gabapentin (30 μg), which did not reverse mechanical allodynia, did not induce conditioned place preference. Finally, concurrent injections of i.c.v. gabapentin (100 μg) and intrathecal yohimbine, an α2-receptor antagonist, blocked preference for the gabapentin-paired chamber. CONCLUSION: We conclude that pain relief, namely a reduction of pain aversiveness, induced by supraspinal gabapentin administered by an i.c.v. route is secondary to its activation of descending noradrenergic inhibitory controls that block transmission of the “pain” message from the spinal cord to the brain. Wolters Kluwer 2018-07-17 /pmc/articles/PMC6085145/ /pubmed/30123855 http://dx.doi.org/10.1097/PR9.0000000000000659 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Basic Science Juarez-Salinas, Dina L. Braz, Joao M. Hamel, Katherine A. Basbaum, Allan I. Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls |
title | Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls |
title_full | Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls |
title_fullStr | Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls |
title_full_unstemmed | Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls |
title_short | Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls |
title_sort | pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls |
topic | Basic Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085145/ https://www.ncbi.nlm.nih.gov/pubmed/30123855 http://dx.doi.org/10.1097/PR9.0000000000000659 |
work_keys_str_mv | AT juarezsalinasdinal painreliefbysupraspinalgabapentinrequiresdescendingnoradrenergicinhibitorycontrols AT brazjoaom painreliefbysupraspinalgabapentinrequiresdescendingnoradrenergicinhibitorycontrols AT hamelkatherinea painreliefbysupraspinalgabapentinrequiresdescendingnoradrenergicinhibitorycontrols AT basbaumallani painreliefbysupraspinalgabapentinrequiresdescendingnoradrenergicinhibitorycontrols |